CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells

Science Translational Medicine

Volumn 10, Issue 437, 2018, Pages

  Abdel Mohsen, Mohamed ^a   Kuri Cervantes, Leticia ^b   Grau Exposito, Judith ^c   Spivak, Adam M ^d   Nell, Racheal A ^d   Tomescu, Costin ^a   Vadrevu, Surya Kumari ^a   Giron, Leila B ^a   Serra Peinado, Carla ^c   Genescà, Meritxell ^c   Castellví, Josep ^e   Wu, Guoxin ^f   Del Rio Estrada, Perla M ^g   González Navarro, Mauricio ^g   Lynn, Kenneth ^a,b,h   King, Colin T ⁱ   Vemula, Sai ^f   Cox, Kara ^f   Wan, Yanmin ^j   Li, Qingsheng ^j   Mounzer, Karam ^h   Kostman, Jay ^h   Frank, Ian ^b   Paiardini, Mirko ⁱ   Hazuda, Daria ^f   Reyes Terán, Gustavo ^g   Richman, Douglas ^k   Howell, Bonnie ^f   Tebas, Pablo ^b   Martinez Picado, Javier ^l,m,n   Planelles, Vicente ^d   Buzon, Maria J ^c   Betts, Michael R ^b   Montaner, Luis J ^a   more..

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f MERCK RESEARCH LABORATORIES   (United States)

^g INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^h Philadelphia Fight   (United States)

ⁱ EMORY UNIVERSITY   (United States)

^j UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l AIDS Research Institute IrsiCaixa HIVACAT   (Spain)

^m UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

ⁿ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; ANTIRETROVIRUS AGENT; CD32 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; DNA; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; RNA; CCR4 PROTEIN, HUMAN; CCR6 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; FC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; ANTIRETROVIRAL THERAPY; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE; VIRUS LATENCY; LYMPHOCYTE; METABOLISM;

ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; IN VITRO TECHNIQUES; LYMPHOCYTES; RECEPTORS, CCR4; RECEPTORS, CCR6; RECEPTORS, CXCR3; RECEPTORS, IGG;

EID: 85045856078     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aar6759     Document Type: Article

References (53)

1. J. K. Wong, M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, D. D. Richman, Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
2. S. G. Deeks, HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141–155 (2011).
3. J. D. Estes, C. Kityo, F. Ssali, L. Swainson, K. N. Makamdop, G. Q. Del Prete, S. G. Deeks, P. A. Luciw, J. G. Chipman, G. J. Beilman, T. Hoskuldsson, A. Khoruts, J. Anderson, C. Deleage, J. Jasurda, T. E. Schmidt, M. Hafertepe, S. P. Callisto, H. Pearson, T. Reimann, J. Schuster, J. Schoephoerster, P. Southern, K. Perkey, L. Shang, S. W. Wietgrefe, C. V. Fletcher, J. D. Lifson, D. C. Douek, J. M. McCune, A. T. Haase, T. W. Schacker, Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 23, 1271–1276 (2017).
4. Y. Fukazawa, R. Lum, A. A. Okoye, H. Park, K. Matsuda, J. Y. Bae, S. I. Hagen, R. Shoemaker, C. Deleage, C. Lucero, D. Morcock, T. Swanson, A. W. Legasse, M. K. Axthelm, J. Hesselgesser, R. Geleziunas, V. M. Hirsch, P. T. Edlefsen, M. Piatak Jr., J. D. Estes, J. D. Lifson, L. J. Picker, B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132–139 (2015).
5. + T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques. Immunity 47, 776–788.e5 (2017).
6. M. Perreau, A.-L. Savoye, E. De Crignis, J.-M. Corpataux, R. Cubas, E. K. Haddad, L. De Leval, C. Graziosi, G. Pantaleo, Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210, 143–156 (2013).
7. G. M. Laird, C. K. Bullen, D. I. S. Rosenbloom, A. R. Martin, A. L. Hill, C. M. Durand, J. D. Siliciano, R. F. Siliciano, Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J. Clin. Invest. 125, 1901–1912 (2015).
8. J. H. Elliott, F. Wightman, A. Solomon, K. Ghneim, J. Ahlers, M. J. Cameron, M. Z. Smith, T. Spelman, J. McMahon, P. Velayudham, G. Brown, J. Roney, J. Watson, M. H. Prince, J. F. Hoy, N. Chomont, R. Fromentin, F. A. Procopio, J. Zeidan, S. Palmer, L. Odevall, R. W. Johnstone, B. P. Martin, E. Sinclair, S. G. Deeks, D. J. Hazuda, P. U. Cameron, R.-P. Sékaly, S. R. Lewin, Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLOS Pathog. 10, e1004473 (2014).
9. R. Olesen, S. Vigano, T. A. Rasmussen, O. S. Søgaard, Z. Ouyang, M. Buzon, A. Bashirova, M. Carrington, S. Palmer, C. R. Brinkmann, X. G. Yu, L. Østergaard, M. Tolstrup, M. Lichterfeld, Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J. Virol. 89, 10176–10189 (2015).
10. A. M. Spivak, A. Andrade, E. Eisele, R. Hoh, P. Bacchetti, N. N. Bumpus, F. Emad, R. Buckheit III, E. F. McCance-Katz, J. Lai, M. Kennedy, G. Chander, R. F. Siliciano, J. D. Siliciano, S. G. Deeks, A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1–infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883–890 (2014).
11. + T cells after multiple doses of vorinostat. J. Infect. Dis. 210, 728–735 (2014).
12. N. M. Archin, A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc, A. M. Crooks, D. C. Parker, E. M. Anderson, M. F. Kearney, M. C. Strain, D. D. Richman, M. G. Hudgens, R. J. Bosch, J. M. Coffin, J. J. Eron, D. J. Hazuda, D. M. Margolis, Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
13. J. H. Elliott, J. H. McMahon, C. C. Chang, S. A. Lee, W. Hartogensis, N. Bumpus, R. Savic, J. Roney, R. Hoh, A. Solomon, M. Piatak, R. J. Gorelick, J. Lifson, P. Bacchetti, S. G. Deeks, S. R. Lewin, Short-term administration of disulfiram for reversal of latent HIV infection: A phase 2 dose-escalation study. Lancet HIV 2, e520–e529 (2015).
14. O. S. Søgaard, M. E. Graversen, S. Leth, R. Olesen, C. R. Brinkmann, S. K. Nissen, A. S. Kjaer, M. H. Schleimann, P. W. Denton, W. J. Hey-Cunningham, K. K. Koelsch, G. Pantaleo, K. Krogsgaard, M. Sommerfelt, R. Fromentin, N. Chomont, T. A. Rasmussen, L. Østergaard, M. Tolstrup, The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLOS Pathog. 11, e1005142 (2015).
15. R. J. Biggar, A. K. Chaturvedi, J. J. Goedert, E. A. Engels; HIV/AIDS Cancer Match Study, AIDS-related cancer and severity of immunosuppression in persons with AIDS. J. Natl. Cancer Inst. 99, 962–972 (2007).
16. A. Carbone, C. C. Volpi, A. V. Gualeni, A. Gloghini, Epstein-Barr virus associated lymphomas in people with HIV. Curr. Opin. HIV AIDS 12, 39–46 (2017).
17. A. Zucchetto, S. Virdone, M. Taborelli, E. Grande, L. Camoni, M. Pappagallo, V. Regine, F. Grippo, J. Polesel, L. Dal Maso, B. Suligoi, L. Frova, D. Serraino, Non-AIDS-defining cancer mortality: Emerging patterns in the late HAART era. J. Acquir. Immune Defic. Syndr. 73, 190–196 (2016).
18. A. J. Rodger, R. Lodwick, M. Schechter, S. Deeks, J. Amin, R. Gilson, R. Paredes, E. Bakowska, F. N. Engsig, A. Phillips; INSIGHT SMART, ESPRIT Study Groups, Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27, 973–979 (2013).
19. S. Grinspoon, A. Carr, Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352, 48–62 (2005).
20. P. W. Hunt, H. L. Cao, C. Muzoora, I. Ssewanyana, J. Bennett, N. Emenyonu, A. Kembabazi, T. B. Neilands, D. R. Bangsberg, S. G. Deeks, J. N. Martin, Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 25, 2123–2131 (2011).
21. J. L. Lyons, H. Uno, P. Ancuta, A. Kamat, D. J. Moore, E. J. Singer, S. Morgello, D. Gabuzda, Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J. Acquir. Immune Defic. Syndr. 57, 371–379 (2011).
22. N. G. Sandler, H. Wand, A. Roque, M. Law, M. C. Nason, D. E. Nixon, C. Pedersen, K. Ruxrungtham, S. R. Lewin, S. Emery, J. D. Neaton, J. M. Brenchley, S. G. Deeks, I. Sereti, D. C. Douek; INSIGHT SMART Study Group, Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203, 780–790 (2011).
23. C. Tincati, G. M. Bellistrì, M. Casana, E. Merlini, L. Comi, F. Bai, E. Sinigaglia, M. Cristina, G. Carpani, T. Bini, A. D. Monforte, G. Marchetti, CD8+ hyperactivation and senescence correlate with early carotid intima-media thickness in HIV+ patients with no cardiovascular disease. J. Acquir. Immune Defic. Syndr. 51, 642–644 (2009).
24. B. Descours, G. Petitjean, J.-L. López-Zaragoza, T. Bruel, R. Raffel, C. Psomas, J. Reynes, C. Lacabaratz, Y. Levy, O. Schwartz, J. D. Lelievre, M. Benkirane, CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature 543, 564–567 (2017).
25. + T-cells: A role for low-affinity Fc receptors. Front. Immunol. 7, 215 (2016).
26. M. Sandor, R. G. Lynch, Lymphocyte Fc receptors: The special case of T cells. Immunol. Today 14, 227–231 (1993).
27. W. Engelhardt, J. Matzke, R. E. Schmidt, Activation-dependent expression of low affinity IgG receptors FcRII(CD32) and FcRIII(CD16) in subpopulations of human T lymphocytes. Immunobiology 192, 297–320 (1995).
28. G. P. Sandilands, S. A. MacPherson, E. R. Burnett, A. J. Russell, I. Downie, R. N. M. MacSween, Differential expression of CD32 isoforms following alloactivation of human T cells. Immunology 91, 204–211 (1997).
29. G. R. Starbeck-Miller, V. P. Badovinac, D. L. Barber, J. T. Harty, Cutting edge: Expression of FcRIIB tempers memory CD8 T cell function in vivo. J. Immunol. 192, 35–39 (2014).
30. C. K. Bullen, G. M. Laird, C. M. Durand, J. D. Siliciano, R. F. Siliciano, New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 20, 425–429 (2014).
31. T.-W. Chun, L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y.-H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch-Crovo, R. F. Siliciano, Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188 (1997).
32. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517 (1999).
33. D. Finzi, M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, R. F. Siliciano, Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
34. + T cells using a limiting dilution coculture assay. Methods Mol. Biol. 1354, 239–253 (2016).
35. + T cells. Nat. Med. 9, 727–728 (2003).
36. Y. G. Alevy, J. Tucker, T. Mohanakumar, CD32A (FcRIIa) mRNA expression and regulation in blood monocytes and cell lines. Mol. Immunol. 29, 1289–1297 (1992).
37. C. Deleage, S. W. Wietgrefe, G. Del Prete, D. R. Morcock, X. P. Hao, M. Piatak Jr., J. Bess, J. L. Anderson, K. E. Perkey, C. Reilly, J. M. McCune, A. T. Haase, J. D. Lifson, T. W. Schacker, J. D. Estes, Defining HIV and SIV reservoirs in lymphoid tissues. Pathog. Immun. 1, 68–106 (2016).
38. K. Tenner-Racz, H.-J. Stellbrink, J. van Lunzen, C. Schneider, J.-P. Jacobs, B. Raschdorff, G. Großschupff, R. M. Steinman, P. Racz, The unenlarged lymph nodes of HIV-1–infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J. Exp. Med. 187, 949–959 (1998).
39. M. P. Bronnimann, P. J. Skinner, E. Connick, The B-cell follicle in HIV infection: Barrier to a cure. Front. Immunol. 9, 20 (2018).
40. M. Wittner, G. A. Dunay, S. Kummer, M. Bockhorn, A. Hüfner, S. Schmiedel, O. Degen, J. van Lunzen, J. M. Eberhard, J. Schulze Zur Wiesch, CD32 expression of different memory T cell subpopulations in the blood and lymph nodal tissue of HIV patients and healthy controls correlates with immune activation. J. Acquir. Immune Defic. Syndr. 77, 345–349 (2018).
41. M. Moonis, B. Lee, R. T. Bailer, Q. Luo, L. J. Montaner, CCR5 and CXCR4 expression correlated with X4 and R5 HIV-1 infection yet not sustained replication in Th1 and Th2 cells. AIDS 15, 1941–1949 (2001).
42. N. Orlova-Fink, F. Z. Chowdhury, X. Sun, S. Harrington, E. S. Rosenberg, X. G. Yu, M. Lichterfeld, Preferential susceptibility of Th9 and Th2 CD4+ T cells to X4-tropic HIV-1 infection. AIDS 31, 2211–2215 (2017).
43. + T cells from colon and blood during antiretroviral therapy. AIDS 31, 35–48 (2017).
44. + T cells are highly permissive to HIV-1 infection. J. Immunol. 184, 1604–1616 (2010).
45. +Th17 cells via a genome-wide transcriptional approach. Retrovirology 12, 102 (2015).
46. A. Pincetic, S. Bournazos, D. J. DiLillo, J. Maamary, T. T. Wang, R. Dahan, B.-M. Fiebiger, J. V. Ravetch, Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15, 707–716 (2014).
47. M.-C. Veri, S. Gorlatov, H. Li, S. Burke, S. Johnson, J. Stavenhagen, K. E. Stein, E. Bonvini, S. Koenig, Monoclonal antibodies capable of discriminating the human inhibitory Fc-receptor IIB (CD32B) from the activating Fc-receptor IIA (CD32A): Biochemical, biological and functional characterization. Immunology 121, 392–404 (2007).
48. + T cells as a major niche for HIV-1 transcription in HIV-infected patients. mBio 8, e00876–e17 (2017).
49. J.-C. Grivel, L. Margolis, Use of human tissue explants to study human infectious agents. Nat. Protoc. 4, 256–269 (2009).
50. J. Qualai, J. Cantero, L.-X. Li, J. M. Carrascosa, E. Cabré, O. Dern, L. Sumoy, G. Requena, S. J. McSorley, M. Genescà, Adhesion molecules associated with female genital tract infection. PLOS ONE 11, e0156605 (2016).
51. F. A. Procopio, R. Fromentin, D. A. Kulpa, J. H. Brehm, A.-G. Bebin, M. C. Strain, D. D. Richman, U. O’Doherty, S. Palmer, F. M. Hecht, R. Hoh, R. J. O. Barnard, M. D. Miller, D. J. Hazuda, S. G. Deeks, R.-P. Sékaly, N. Chomont, A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine 2, 874–883 (2015).
52. E. S. Ryan, L. Micci, R. Fromentin, S. Paganini, C. S. McGary, K. Easley, N. Chomont, M. Paiardini, Loss of function of intestinal IL-17 and IL-22 producing cells contributes to inflammation and viral persistence in SIV-infected rhesus macaques. PLOS Pathog. 12, e1005412 (2016).
53. + T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proc. Natl. Acad. Sci. U.S.A. 106, 8015–8020 (2009).